deferiprone has been researched along with fluorexon in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Barnabé, N; Hasinoff, BB; Venkataram, S; Zastre, JA | 1 |
Fibach, E; Prus, E | 1 |
Baccan, MM; Chiarelli-Neto, O; Espósito, BP; Pereira, RM | 1 |
Connor, JR; Huang, X; Kim, Y; Stahl, MC | 1 |
4 other study(ies) available for deferiprone and fluorexon
Article | Year |
---|---|
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cell Survival; Cells, Cultured; Deferiprone; Doxorubicin; Electron Spin Resonance Spectroscopy; Fluoresceins; Free Radicals; Indicators and Reagents; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Myocytes, Cardiac; Oxidation-Reduction; Pyridones; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
The labile iron pool in human erythroid cells.
Topics: Antigens, CD; beta-Thalassemia; Bone Marrow Cells; Cells, Cultured; Deferiprone; Erythroblasts; Erythrocytes; Erythropoiesis; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Humans; Iron; Iron Chelating Agents; Pyridones; Reticulocytes; Transferrin | 2008 |
Quercetin as a shuttle for labile iron.
Topics: Animals; Antioxidants; Ascorbic Acid; Binding, Competitive; Cattle; Coordination Complexes; Deferiprone; Ferrous Compounds; Fluoresceins; HeLa Cells; Humans; Iron; Iron Chelating Agents; Oxidation-Reduction; Pyridones; Quaternary Ammonium Compounds; Quercetin; Rutin; Transferrin | 2012 |
H63D variant of the homeostatic iron regulator (HFE) gene alters α-synuclein expression, aggregation, and toxicity.
Topics: alpha-Synuclein; Animals; Autophagy; Cells, Cultured; Deferiprone; Fluoresceins; Gene Knockdown Techniques; Hemochromatosis Protein; Humans; Immunohistochemistry; Iron Chelating Agents; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mutation; Psychomotor Performance; Transcription Factors | 2020 |